Key result
In a European registry of 2420 patients with chronic ischaemic cardiovascular disease, discharge prescription rates were high for statins (92.7%), aspirin (90.3%), and ACEi/ARBs (82.8%).
Observational (n=2,420)
Yes
Answers are grounded in this paper and cite their sources.
The CICD-Pilot registry demonstrates high rates of guideline-directed medical therapy prescription at discharge for European patients with chronic ischemic cardiovascular disease, though heterogeneity remains across different clinical presentations.
AIMS: Chronic ischaemic cardiovascular disease (CICD) is a major cause of mortality and morbidity worldwide. The primary objective of the CICD-Pilot registry was to describe the clinical characteristics and management modalities across Europe in a broad spectrum of patients with CICD. METHODS AND RESULTS: The CICD-Pilot registry is an international prospective observational longitudinal registry, conducted in 100 centres from 10 countries selected to reflect the diversity of health systems and care attitudes across Europe. From April 2013 to December 2014, 2420 consecutive CICD patients with non-ST-elevation acute coronary syndrome (n = 755) and chronic stable coronary artery disease (n = 1464), of whom 933 (63.7%) were planned for elective coronary intervention, or with peripheral artery disease (PAD) (n = 201), were enrolled (30.5% female patients). Mean age was 66.6 ± 10.9 years. The following risk factors were reported: smoking 54.6%, diabetes mellitus 29.2%, hypertension 82.6%, and hypercholesterolaemia 74.1%. Assessment of cardiac function was made in 69.5% and an exercise stress test in 21.2% during/within 1 year preceding admission. New stress imaging modalities were applied in a minority of patients. A marked increase was observed at discharge in the rate of prescription of angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers (82.8%), beta-blockers (80.2%), statins (92.7%), aspirin (90.3%), and clopidogrel (66.8%). Marked differences in clinical profile and treatment modalities were observed across the four cohorts. CONCLUSION: The CICD-Pilot registry suggests that implementation of guideline-recommended therapies has improved since the previous surveys but that important heterogeneity exists in the clinical profile and treatment modalities in the different cohorts of patients enrolled with a broad spectrum of CICDs.
No takes yet. Share an insight, caveat, or question.
Komajda et al. (2015) conducted an observational in Chronic ischaemic cardiovascular disease (CICD) (n=2,420). Clinical management was evaluated on Clinical characteristics and management modalities. In a European registry of 2420 patients with chronic ischaemic cardiovascular disease, discharge prescription rates were high for statins (92.7%), aspirin (90.3%), and ACEi/ARBs (82.8%).
Synapse has enriched 10 related papers. Consider them for comparative context: